98 related articles for article (PubMed ID: 23067924)
1. A therapeutic opportunity that needs to be optimized.
Jolobe OM
Am Heart J; 2012 Oct; 164(4):e11. PubMed ID: 23067924
[No Abstract] [Full Text] [Related]
2. Global systolic load, left ventricular hypertrophy, and atrial fibrillation.
Bang CN; Greve AM; Wachtell K; Kober L
Am Heart J; 2012 Oct; 164(4):e13. PubMed ID: 23067925
[No Abstract] [Full Text] [Related]
3. Agents with antialdosterone properties should be the preferred diuretics for reducing hypertension related atrial fibrillation.
Jolobe OM
Eur J Intern Med; 2010 Feb; 21(1):55. PubMed ID: 20122621
[No Abstract] [Full Text] [Related]
4. Atrial fibrillation and blood pressure.
Harv Heart Lett; 2009 Jun; 19(10):6. PubMed ID: 19681208
[No Abstract] [Full Text] [Related]
5. Systolic hypertension is also the neglected stepsister of aortic stenosis.
Jolobe OM
Am J Med; 2008 Sep; 121(9):e21, author reply e23. PubMed ID: 18724948
[No Abstract] [Full Text] [Related]
6. [Atrial fibrillation as end point of hypertension. Can antihypertensive therapy prevent it?].
Geller JC
MMW Fortschr Med; 2003 Nov; 145(47):38-41. PubMed ID: 14725032
[TBL] [Abstract][Full Text] [Related]
7. [A suitable antihypertensive drug of significance. Protection of heart, brain and kidney is decisive].
MMW Fortschr Med; 2005 May; 147(19):49. PubMed ID: 15940939
[No Abstract] [Full Text] [Related]
8. [Atrial fibrillation as endpoint in studies of arterial hypertension].
Jung J
Dtsch Med Wochenschr; 2003 Nov; 128(47):2493-6. PubMed ID: 14628258
[No Abstract] [Full Text] [Related]
9. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
[TBL] [Abstract][Full Text] [Related]
10. [Hypertensive patient with enlarged heart. Caution, risk of atrial fibrillation!].
MMW Fortschr Med; 2006 May; 148(21):62. PubMed ID: 16796195
[No Abstract] [Full Text] [Related]
11. [Combined heart protection for the hypertensive patient].
MMW Fortschr Med; 2013 Jan; 155(1):66-7. PubMed ID: 23573728
[No Abstract] [Full Text] [Related]
12. Resistant hypertension or aortic stenosis? Know the difference.
Doherty CL
Nurse Pract; 2010 May; 35(5):11-5. PubMed ID: 20395756
[No Abstract] [Full Text] [Related]
13. [An apparent improvement of hypertension].
Kilkki E
Duodecim; 1998; 114(14):1416-9. PubMed ID: 11552250
[No Abstract] [Full Text] [Related]
14. Management of Hypertension in Patients with Aortic Valvular Stenosis.
Agnihotri K; Singh V; Panaich SS; Patel NJ; Patel N; Arora S; Pau D; Deshmukh A; Badheka AO
Curr Hypertens Rev; 2017; 13(1):41-45. PubMed ID: 28245786
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive Treatments in Patients Affected by Aortic Valve Stenosis.
Poggio P; Folesani G; Raffa GM; Songia P; Valenti V; Myasoedova V; Parolari A
Curr Pharm Des; 2017; 23(8):1188-1194. PubMed ID: 27881062
[TBL] [Abstract][Full Text] [Related]
16. [Antihypertensive agents used as first line agents: beta-blockers under pressure].
Burnier M; Pechère A; Waeber B
Rev Med Suisse; 2006 Sep; 2(78):2019-20. PubMed ID: 17019836
[No Abstract] [Full Text] [Related]
17. Eplerenone (GD Searle & Co).
Martin J; Krum H
Curr Opin Investig Drugs; 2001 Apr; 2(4):521-4. PubMed ID: 11566010
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and pharmacologic approach to patients with resistant hypertension.
Adams M; Bellone JM; Wright BM; Rutecki GW
Postgrad Med; 2012 Jan; 124(1):74-82. PubMed ID: 22314117
[TBL] [Abstract][Full Text] [Related]
19. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke?
Solun B; Marcoviciu D; Dicker D
Eur J Intern Med; 2009 Mar; 20(2):125-31. PubMed ID: 19327599
[TBL] [Abstract][Full Text] [Related]
20. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology to clinical trials.
Boos CJ; Lip GY
J Hum Hypertens; 2005 Nov; 19(11):855-9. PubMed ID: 16094406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
